Symbols

KNSA

Kiniksa·NASDAQ

--(--)

KNSA fundamentals

KNSA Q4 2025 Earnings

Kiniksa (KNSA) released its earnings on Feb 24, 2026: revenue was 202.13M (YoY +64.95%), beat estimates; EPS was 0.17 (YoY +241.67%), missed estimates.

Revenue / YoY

202.13M

+64.95%

EPS / YoY

0.17

+241.67%

Report date

Feb 24, 2026

KNSA Earnings Call Summary for Q4,2025

Revenue Growth: ARCALYST up 65% YoY in Q4, full year $677.6M, driven by IL-1 inhibition adoption.
Pipeline Momentum: KPL-387 Phase II enrollment ongoing, targeting 2028-2029 approval; KPL-1161 set to enter clinic.
Market Expansion: 18% penetration in 2+ recurrence population, 20% first recurrence prescriptions, 75% patient preference for KPL-387.
Financial Strength: $414M cash, $59M net income in 2025, guiding to $900M-$920M 2026 revenue.

Earnings

EPS

Revenue

Revenue & Expenses

KNSA has released its 2025 Q4 earnings report, with revenue of 202.13M, reflecting a YoY change of 64.95%, and net profit of 14.20M, showing a YoY change of 259.75%. The Sankey diagram below clearly presents KNSA's revenue sources and cost distribution.

Key Indicators

Kiniksa (KNSA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Kiniksa (KNSA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Kiniksa (KNSA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Kiniksa (KNSA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown